JP2018501292A5 - - Google Patents

Download PDF

Info

Publication number
JP2018501292A5
JP2018501292A5 JP2017536831A JP2017536831A JP2018501292A5 JP 2018501292 A5 JP2018501292 A5 JP 2018501292A5 JP 2017536831 A JP2017536831 A JP 2017536831A JP 2017536831 A JP2017536831 A JP 2017536831A JP 2018501292 A5 JP2018501292 A5 JP 2018501292A5
Authority
JP
Japan
Prior art keywords
oral composition
solid oral
composition according
release solid
coated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017536831A
Other languages
English (en)
Japanese (ja)
Other versions
JP6910950B2 (ja
JP2018501292A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from US14/993,294 external-priority patent/US9833411B2/en
Publication of JP2018501292A publication Critical patent/JP2018501292A/ja
Publication of JP2018501292A5 publication Critical patent/JP2018501292A5/ja
Application granted granted Critical
Publication of JP6910950B2 publication Critical patent/JP6910950B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017536831A 2015-01-12 2016-01-12 固形経口剤形 Expired - Fee Related JP6910950B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562102263P 2015-01-12 2015-01-12
US62/102,263 2015-01-12
US14/993,294 2016-01-12
US14/993,294 US9833411B2 (en) 2015-01-12 2016-01-12 Solid oral dosage forms
PCT/US2016/012970 WO2016115082A1 (en) 2015-01-12 2016-01-12 Solid oral dosage forms

Publications (3)

Publication Number Publication Date
JP2018501292A JP2018501292A (ja) 2018-01-18
JP2018501292A5 true JP2018501292A5 (https=) 2019-02-28
JP6910950B2 JP6910950B2 (ja) 2021-07-28

Family

ID=56366726

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017536831A Expired - Fee Related JP6910950B2 (ja) 2015-01-12 2016-01-12 固形経口剤形

Country Status (10)

Country Link
US (2) US9833411B2 (https=)
EP (1) EP3244878B1 (https=)
JP (1) JP6910950B2 (https=)
KR (1) KR102294577B1 (https=)
CN (1) CN107427469B (https=)
AU (1) AU2016206950B2 (https=)
CA (1) CA2973099C (https=)
DK (1) DK3244878T3 (https=)
ES (1) ES2929218T3 (https=)
WO (1) WO2016115082A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9457086B2 (en) 2013-03-05 2016-10-04 Enteris Biopharma, Inc. Pharmaceuticals for oral delivery
CN118634202A (zh) * 2016-08-05 2024-09-13 帕克治疗公司 室温稳定的口服降钙素制剂
EP3459527B1 (en) * 2017-09-20 2022-11-23 Tillotts Pharma Ag Method for preparing a solid dosage form comprising antibodies by wet granulation, extrusion and spheronization
CN108065443B (zh) * 2017-12-30 2020-02-28 厦门金达威维生素有限公司 斥水型双包被微胶囊及其制备方法
EP3610862A1 (en) * 2018-08-14 2020-02-19 Apillet APS Novel oral composition
MX2022001975A (es) * 2019-08-16 2022-03-11 Applied Molecular Transport Inc Composiciones, formulaciones y produccion y purificacion de interleucinas.
CN114901262A (zh) * 2019-11-04 2022-08-12 辛克鲁斯制药控股有限公司 X842的口服制剂
EP4096698A1 (en) 2020-01-28 2022-12-07 Genentech, Inc. Il15/il15r alpha heterodimeric fc-fusion proteins for the treatment of cancer
CN112956699A (zh) * 2021-01-27 2021-06-15 上海海洋大学 一种降血糖肽肠溶固体分散体及其制备方法
US20250073309A1 (en) * 2021-04-08 2025-03-06 Enteris Biopharma, Inc. Methods of treatment of pediatric puberty using oral formulations of leuprolide
MX2024005292A (es) 2021-11-05 2024-05-17 Cinclus Pharma Holding Ab Publ Polimorfos de la sal de clorhidrato de glurato de linaprazan.
JP2025519656A (ja) 2022-06-13 2025-06-26 ビー．エー．アイ． ラボラトリーズ， エルエルシー インターロイキン－１３結合環状オリゴペプチドおよびその使用方法

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956926A (en) * 1958-09-23 1960-10-18 American Cyanamid Co Coated citric acid particles
DE3346953A1 (de) 1983-12-24 1985-08-14 Organogen Medizinisch-Molekularbiologische Forschungsgesellschaft mbH, 6900 Heidelberg Cardiodilatin, ein neues peptidhormon und verfahren zu seiner herstellung
US6319685B1 (en) 1984-09-27 2001-11-20 Unigene Laboratories, Inc. Alpha-amidating enzyme compositions and processes for their production and use
US4708934A (en) 1984-09-27 1987-11-24 Unigene Laboratories, Inc. α-amidation enzyme
US4849227A (en) 1986-03-21 1989-07-18 Eurasiam Laboratories, Inc. Pharmaceutical compositions
US5789234A (en) 1987-08-14 1998-08-04 Unigene Laboratories, Inc. Expression systems for amidating enzyme
FR2628429B1 (fr) 1988-03-08 1990-12-28 Transgene Sa Variants de l'hirudine, leurs utilisations et les procedes pour les obtenir
US5196404B1 (en) 1989-08-18 1996-09-10 Biogen Inc Inhibitors of thrombin
AU653026B2 (en) 1991-06-07 1994-09-15 Teikoku Seiyaku Kabushiki Kaisha Physiologically active polypeptide-containing pharmaceutical composition
US5330759A (en) * 1992-08-26 1994-07-19 Sterling Winthrop Inc. Enteric coated soft capsules and method of preparation thereof
US5912014A (en) * 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6384016B1 (en) 1998-03-13 2002-05-07 Novo Nordisk A/S Stabilized aqueous peptide solutions
WO1998046722A1 (en) 1997-04-16 1998-10-22 Unigene Laboratories Inc. Direct expression of peptides into culture media
UA53716C2 (uk) 1997-06-25 2003-02-17 Пфайзер Продактс Інк. Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти)
US6761903B2 (en) * 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US20010055648A1 (en) 1999-12-14 2001-12-27 Primera Foods Corporation Apparatus and process for coating particles
AU783952B2 (en) 2000-02-04 2006-01-05 Unigene Laboratories, Inc. Nasal calcitonin formulations
CA2415643C (en) * 2000-07-17 2010-11-16 Yamanouchi Pharmaceutical Co., Ltd. Pharmaceutical composition for oral use with improved absorption
US6673574B2 (en) 2000-11-30 2004-01-06 Unigene Laboratories Inc. Oral delivery of peptides using enzyme-cleavable membrane translocators
US7316819B2 (en) 2001-03-08 2008-01-08 Unigene Laboratories, Inc. Oral peptide pharmaceutical dosage form and method of production
CA2445860A1 (en) 2001-04-30 2002-11-07 Shire Laboratories Inc. Pharmaceutical composition including ace/nep inhibitors and bioavailability enhancers
US8088734B2 (en) 2003-01-21 2012-01-03 Unigene Laboratories Inc. Oral delivery of peptides
WO2004089985A1 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S Stable pharmaceutical compositions
US20050123507A1 (en) 2003-06-30 2005-06-09 Mahmoud Ameri Formulations for coated microprojections having controlled solubility
US20060247167A1 (en) 2003-09-01 2006-11-02 Novo Nordisk A/S Stable formulations of peptides
EP1758927A4 (en) 2004-01-21 2008-09-17 Unigene Lab Inc PARATHYROID HORMONE AMIDE FRAGMENTS AND USES THEREOF
US8227241B2 (en) 2004-03-12 2012-07-24 Unigene Laboratories, Inc. Bacterial host cell for the direct expression of peptides
KR20050104152A (ko) 2004-04-28 2005-11-02 최승호 경구용 약물의 흡수를 증진하는 약제학적 조성물
US20050282756A1 (en) 2004-06-18 2005-12-22 Mehta Nozer M Oral delivery of peptide pharmaceutical compositions
US20060046962A1 (en) * 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
WO2006026592A2 (en) 2004-08-27 2006-03-09 Spherics, Inc. Oral administration of poorly absorbed drugs, methods and compositions related thereto
GB0419355D0 (en) * 2004-08-31 2004-09-29 Novartis Ag Organic compounds
WO2006051103A2 (en) 2004-11-12 2006-05-18 Novo Nordisk A/S Stable formulations of peptides
CN101056650A (zh) 2004-11-12 2007-10-17 诺和诺德公司 促胰岛素肽的稳定制剂
US7445911B2 (en) 2004-11-24 2008-11-04 Unigene Laboratories Inc. Enzymatic reactions in the presence of keto acids
WO2006125762A1 (en) 2005-05-25 2006-11-30 Novo Nordisk A/S Stabilized polypeptide formulations
AU2006261909B2 (en) 2005-06-24 2011-08-11 Enteris Biopharma, Inc. Cell lines for expressing enzyme useful in the preparation of amidated products
US8093207B2 (en) 2005-12-09 2012-01-10 Unigene Laboratories, Inc. Fast-acting oral peptide pharmaceutical products
BRPI0620430A2 (pt) 2005-12-22 2011-11-08 Wyeth Corp métodos para tratar infecções do trato gastrointestinal com tigeciclina
WO2007075794A2 (en) * 2005-12-22 2007-07-05 Wyeth Oral formulations comprising tigecycline
JP2009523784A (ja) * 2006-01-16 2009-06-25 ジュビラント・オルガノシス・リミテッド 酸不安定化合物の安定な医薬製剤およびその製造方法
EP2086515A2 (en) * 2006-03-02 2009-08-12 Vaunnex, Inc. Rate-controlled bioadhesive oral dosage formulations
MX350380B (es) * 2006-05-09 2017-09-05 SpecGx LLC Formas de dosificacion solida de liberacion modificada en el orden de cero.
KR20190028822A (ko) * 2007-04-25 2019-03-19 사이토크로마 인코포레이티드 비타민 ｄ 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물
US8377863B2 (en) 2007-05-29 2013-02-19 Unigene Laboratories Inc. Peptide pharmaceutical for oral delivery
EP2155167A2 (en) * 2007-06-04 2010-02-24 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
CN101380461B (zh) * 2008-09-27 2011-09-07 吴建中 高效的胸腺肽肠溶片和注射用胸腺肽
US20100256060A1 (en) 2009-04-02 2010-10-07 Unigene Laboratories Inc. Peptide pharmaceuticals for nasal delivery
JP2012144436A (ja) * 2009-04-30 2012-08-02 Takeda Chem Ind Ltd 併用剤
US20120071410A1 (en) 2010-09-21 2012-03-22 Unigene Laboratories Inc. Calcitonin products and therapies for treating inflammatory or degenerative diseases
SI2651398T1 (en) 2010-12-16 2018-04-30 Novo Nordisk A/S SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND SOL N- (8- (2-HYDROXYBENZOIL) AMINO) CAPRICULATE ACIDS
WO2012098187A1 (en) 2011-01-19 2012-07-26 Novo Nordisk A/S Glp-1 compositions
EP2665470A1 (en) 2011-01-19 2013-11-27 Novo Nordisk A/S Glp-1 particles and compositions
CA2839408A1 (en) * 2011-06-14 2012-12-20 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
US9102753B2 (en) 2011-06-15 2015-08-11 Ugp Therapeutics, Inc. Anti-inflammatory pharmaceutical products
ES2965469T3 (es) 2012-03-22 2024-04-15 Novo Nordisk As Composiciones que comprenden un agente de suministro y preparación de estas
JP6517690B2 (ja) 2012-06-20 2019-05-22 ノヴォ ノルディスク アー／エス ペプチド及び送達剤を含む錠剤製剤
IN2015DN03132A (https=) * 2012-09-17 2015-10-02 Tarix Pharmaceuticals Ltd
WO2014060472A1 (en) 2012-10-17 2014-04-24 Novo Nordisk A/S Fatty acid acylated amino acids for oral peptide delivery
US9457086B2 (en) 2013-03-05 2016-10-04 Enteris Biopharma, Inc. Pharmaceuticals for oral delivery
KR102272671B1 (ko) 2013-05-02 2021-07-06 노보 노르디스크 에이/에스 Glp-1 화합물의 경구 투여
JP2016524617A (ja) 2013-05-30 2016-08-18 ノヴォ ノルディスク アー／エス 糖尿病の治療のための新規な経口医薬組成物
WO2015162195A1 (en) 2014-04-23 2015-10-29 Novo Nordisk A/S Fatty acid acylated amino acids for oral peptide delivery
US20180263915A1 (en) 2015-01-29 2018-09-20 Novo Nordisk A/S Pharmaceutical Composition for Oral GLP-1 Administration Comprising a Tablet Core and Immediate Release Coating
JP7211704B2 (ja) 2015-01-29 2023-01-24 ノヴォ ノルディスク アー／エス Ｇｌｐ－１アゴニスト及び腸溶コーティングを含む錠剤

Similar Documents

Publication Publication Date Title
JP2018501292A5 (https=)
JP2011105760A5 (https=)
ES2560251T3 (es) Farmacéutico peptídico para la administración oral
AU2016206950B2 (en) Solid oral dosage forms
JP2007519741A (ja) 胃腸特異的複数薬物放出システム
US10172794B2 (en) Controlled release dosage form for once daily administration of dimethyl fumarate
JP2017504590A5 (https=)
JP2011519867A5 (https=)
JP2015531749A5 (https=)
US9795592B2 (en) Pharmaceutical formulations of vildagliptin
JP2011528344A (ja) 胃腸管において酵素分解に付される、および／または吸収されにくい薬剤の結腸への送達系
EP4019003A1 (en) Pharmaceutical formulations of linagliptin
JP2015504094A5 (https=)
JP2000247911A (ja) 大腸用吸収促進剤
CN113117050A (zh) 多肽组合物及其用途
KR20130121717A (ko) 위체류 약물전달 시스템을 이용한 서방성 제제
CN105796503A (zh) 一种沙格列汀微丸及其制剂
US20030175351A1 (en) Pharmaceutical composition for oral use with improved absorption
EP4292583A1 (en) Composition in which absorbability of poorly-absorbable drug is improved
Lee et al. Controlled release of tamsulosin from enteric coated sustained-release matrices with aqueous microchannels
EP3545951B1 (en) Oral tablet composition comprising dexlansoprazole, oral tablet comprising same and method for manufacturing same
CN120860230A (zh) 一种包含肽类药物活性分子的药物组合物及其用途
CN108969487A (zh) 雷贝拉唑肠溶干混悬剂及其制备方法
CN105982889A (zh) 抗流感病毒的药物组合物及其应用
HK40014763A (en) Room temperature stable oral calcitonin formulation